ArticleEuropean journal of clinical pharmacology2026
Bleeding risk of rivaroxaban and edoxaban with and without amiodarone in atrial fibrillation patients: a prospective cohort study.
Article in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundRivaroxaban and edoxaban are commonly used for stroke prevention in patients with atrial fibrillation (AF). This study aimed to compare the bleeding risk between rivaroxaban and edoxaban in patients with atrial fibrillation, both with and without the combination of amiodarone.
methodsIn this prospective cohort study, participants were divided into four groups: rivaroxaban monotherapy, edoxaban monotherapy, rivaroxaban combined with amiodarone, and edoxaban combined with amiodarone. Propensity score matching (PSM) was used to control for confounding factors. The primary endpoint was the time to the first occurrence of bleeding (major, CRNM, or minor).
resultsA total of 910 patients were included. The bleeding risk was similar between the rivaroxaban (9.0%) and edoxaban (13.5%) monotherapy groups (P = 0.403). However, the bleeding risk in the rivaroxaban-amiodarone group was significantly higher than in the edoxaban-amiodarone group in the PSM analysis (HR = 2.015, 95% CI = 1.026–3.958, P = 0.042). Patients receiving standard-dose rivaroxaban with amiodarone had a significantly higher bleeding risk than those receiving edoxaban with amiodarone (HR = 2.678, 95% CI = 1.017–7.045, P = 0.046). Additionally, rivaroxaban with amiodarone was associated with a significantly higher bleeding risk compared to edoxaban with amiodarone in patients with renal dysfunction (HR = 2.186, 95% CI = 1.016–4.702, P = 0.045).
conclusionWhen combined with amiodarone, rivaroxaban was associated with a higher bleeding risk compared to edoxaban, particularly in patients receiving the standard dose of anticoagulants or with impaired renal function. This study the name of the trial register: Zhongshan Hospital, Fudan University, Registration number: ChiCTR2200062662, Date of Registration: 2022-08-15.
Indexed as
Identifiers
41661331What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.